TY - JOUR
T1 - Calibration of computational tools for missense variant pathogenicity classification and ClinGen recommendations for PP3/BP4 criteria
AU - ClinGen Sequence Variant Interpretation Working Group
AU - Pejaver, Vikas
AU - Byrne, Alicia B.
AU - Feng, Bing Jian
AU - Pagel, Kymberleigh A.
AU - Mooney, Sean D.
AU - Karchin, Rachel
AU - O'Donnell-Luria, Anne
AU - Harrison, Steven M.
AU - Tavtigian, Sean V.
AU - Greenblatt, Marc S.
AU - Biesecker, Leslie G.
AU - Radivojac, Predrag
AU - Brenner, Steven E.
AU - Tayoun, Ahmad A.
AU - Berg, Jonathan S.
AU - Cutting, Garry R.
AU - Ellard, Sian
AU - Kang, Peter
AU - Karbassi, Izabela
AU - Mester, Jessica
AU - Pesaran, Tina
AU - Plon, Sharon E.
AU - Rehm, Heidi L.
AU - Strande, Natasha T.
AU - Topper, Scott
N1 - Funding Information:
We thank Drs. Joseph Rothstein and Weiva Sieh for filtering out variants in our set that were present in REVEL's and constituent tools’ training sets. We thank Drs. Panagiotis Katsonis and Olivier Lichtarge for generating prediction scores for the evolutionary action approach. We also thank Drs. John Moult and Shantanu Jain for productive discussions. V.P. was supported by NIH grant K99 LM012992. A.B.B. and S.M.H. were supported by NIH grant U24 HG006834. A.O'D.-L. was supported by NIH grants U24 HG011450, U01 HG011755, and UM1 HG008900. S.V.T. was supported by NIH grants R01 CA121245 and R01 CA264971. M.S.G. was supported by NIH grant U24 CA258119. L.G.B. was supported by NIH grant ZI AHG200359. P.R. and S.E.B. were supported by NIH grant U24 HG007346. P.R. was also supported by NIH grant U01 HG012022. S.E.B. was also supported by NIH grants U41 HG009649 and U24 HG009649 and a research agreement with Tata Consultancy Services. R13 HG006650 supported participants’ conference and working group attendance. ClinGen is primarily funded by the National Human Genome Research Institute (NHGRI) with co-funding from the National Cancer Institute (NCI), through the following grants: U24 HG009649 (to Baylor/Stanford), U24 HG006834 (to Broad/Geisinger), and U24 HG009650 (to UNC/Kaiser). The authors thank Julia Fekecs of NHGRI for graphics support. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The PERCH software, for which B.-J.F. is the inventor, has been non-exclusively licensed to Ambry Genetics Corporation for their clinical genetic testing services and research. B.-J.F. also reports funding and sponsorship to his institution on his behalf from Pfizer Inc. Regeneron Genetics Center LLC. and Astra Zeneca. A.O'D.-L. is a compensated member of the Scientific Advisory Board of Congenica. L.G.B. is an uncompensated member of the Illumina Medical Ethics committee and receives honoraria from Cold Spring Harbor Laboratory Press. V.P. B.-J.F. K.A.P. S.D.M. R.K. A.O'D.-L. and P.R. participated in the development of some of the tools assessed in this study. While every care was taken to mitigate any potential biases in this work, these authors’ participation in method development is noted.
Funding Information:
We thank Drs. Joseph Rothstein and Weiva Sieh for filtering out variants in our set that were present in REVEL’s and constituent tools’ training sets. We thank Drs. Panagiotis Katsonis and Olivier Lichtarge for generating prediction scores for the evolutionary action approach. We also thank Drs. John Moult and Shantanu Jain for productive discussions. V.P. was supported by NIH grant K99 LM012992 . A.B.B. and S.M.H. were supported by NIH grant U24 HG006834 . A.O’D.-L. was supported by NIH grants U24 HG011450 , U01 HG011755 , and UM1 HG008900 . S.V.T. was supported by NIH grants R01 CA121245 and R01 CA264971 . M.S.G. was supported by NIH grant U24 CA258119 . L.G.B. was supported by NIH grant ZI AHG200359 . P.R. and S.E.B. were supported by NIH grant U24 HG007346 . P.R. was also supported by NIH grant U01 HG012022 . S.E.B. was also supported by NIH grants U41 HG009649 and U24 HG009649 and a research agreement with Tata Consultancy Services. R13 HG006650 supported participants’ conference and working group attendance. ClinGen is primarily funded by the National Human Genome Research Institute ( NHGRI ) with co-funding from the National Cancer Institute ( NCI ), through the following grants: U24 HG009649 (to Baylor / Stanford ), U24 HG006834 (to Broad / Geisinger ), and U24 HG009650 (to UNC / Kaiser ). The authors thank Julia Fekecs of NHGRI for graphics support. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Publisher Copyright:
© 2022 The Authors
PY - 2022/12/1
Y1 - 2022/12/1
N2 - Recommendations from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) for interpreting sequence variants specify the use of computational predictors as “supporting” level of evidence for pathogenicity or benignity using criteria PP3 and BP4, respectively. However, score intervals defined by tool developers, and ACMG/AMP recommendations that require the consensus of multiple predictors, lack quantitative support. Previously, we described a probabilistic framework that quantified the strengths of evidence (supporting, moderate, strong, very strong) within ACMG/AMP recommendations. We have extended this framework to computational predictors and introduce a new standard that converts a tool's scores to PP3 and BP4 evidence strengths. Our approach is based on estimating the local positive predictive value and can calibrate any computational tool or other continuous-scale evidence on any variant type. We estimate thresholds (score intervals) corresponding to each strength of evidence for pathogenicity and benignity for thirteen missense variant interpretation tools, using carefully assembled independent data sets. Most tools achieved supporting evidence level for both pathogenic and benign classification using newly established thresholds. Multiple tools reached score thresholds justifying moderate and several reached strong evidence levels. One tool reached very strong evidence level for benign classification on some variants. Based on these findings, we provide recommendations for evidence-based revisions of the PP3 and BP4 ACMG/AMP criteria using individual tools and future assessment of computational methods for clinical interpretation.
AB - Recommendations from the American College of Medical Genetics and Genomics and the Association for Molecular Pathology (ACMG/AMP) for interpreting sequence variants specify the use of computational predictors as “supporting” level of evidence for pathogenicity or benignity using criteria PP3 and BP4, respectively. However, score intervals defined by tool developers, and ACMG/AMP recommendations that require the consensus of multiple predictors, lack quantitative support. Previously, we described a probabilistic framework that quantified the strengths of evidence (supporting, moderate, strong, very strong) within ACMG/AMP recommendations. We have extended this framework to computational predictors and introduce a new standard that converts a tool's scores to PP3 and BP4 evidence strengths. Our approach is based on estimating the local positive predictive value and can calibrate any computational tool or other continuous-scale evidence on any variant type. We estimate thresholds (score intervals) corresponding to each strength of evidence for pathogenicity and benignity for thirteen missense variant interpretation tools, using carefully assembled independent data sets. Most tools achieved supporting evidence level for both pathogenic and benign classification using newly established thresholds. Multiple tools reached score thresholds justifying moderate and several reached strong evidence levels. One tool reached very strong evidence level for benign classification on some variants. Based on these findings, we provide recommendations for evidence-based revisions of the PP3 and BP4 ACMG/AMP criteria using individual tools and future assessment of computational methods for clinical interpretation.
KW - ACMG/AMP recommendations
KW - PP3/BP4 criteria
KW - clinical classification
KW - computational predictors
KW - in silico tools
KW - likelihood ratio
KW - posterior probability
KW - variant interpretation
UR - http://www.scopus.com/inward/record.url?scp=85143380164&partnerID=8YFLogxK
U2 - 10.1016/j.ajhg.2022.10.013
DO - 10.1016/j.ajhg.2022.10.013
M3 - Article
C2 - 36413997
AN - SCOPUS:85143380164
SN - 0002-9297
VL - 109
SP - 2163
EP - 2177
JO - American Journal of Human Genetics
JF - American Journal of Human Genetics
IS - 12
ER -